Nanofàrmacs

IONIZABLE LIPID COMPOUND, LIPID CARRIER COMPRISING SAME AND USE THEREOF

Resumen de: US20260327185A1

0000 The present invention relates to an ionizable lipid compound, a lipid carrier comprising same and the use thereof. Provided in the present invention are a series of compounds as represented by formula (1), a lipid carrier comprising same as an ionizable lipid, a nucleic acid lipid nanoparticle composition and a preparation thereof. A lipid nanoparticle formed from the ionizable lipid can deliver a nucleic acid molecule into the body, so that the transfer rate of a nucleic acid molecule is increased, and the treatment effect of a nucleic acid drug is improved. 0000

LIPID NANOPARTICLE COMPOSITIONS AND METHODS OF USING SAME

Resumen de: US20260325457A1

0000 The present disclosure relates to water-soluble lipid nanoparticle (LNP) compositions comprising a hydrophobic small molecule encapsulated in an LNP that can be dispersed in an aqueous carrier. In certain aspects, the LNP comprises dipalmitoylphosphatidylcholine (DPPC), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), distearoylphosphatidylethanolamine-polyethylene glycol (DSPE-PEG), and cholesterol. The LNP compositions can be used to encapsulate the hydrophobic small molecule 3-2-(4-fluorophenyl)methylimidazo2,1-bthiazol-6-yl-2H-1-benzopyran-2-one (iMDK), an inhibitor of midkine (MDK) for treatment. The LNP compositions can be administered to treat a cancer in an individual in need thereof.

LIPID NANOPARTICLES FOR DELIVERY OF THERAPEUTIC PAYLOADS TO CELLS

Resumen de: AU2025235898A1

The disclosure provides ionizable lipids for constructing lipid nanopartides. The disclosure further provides conjugates comprising a targeting moiety conjugated to a lipid nanoparticle (LNP) encapsulating a. therapeutic agent (i.e., payload) for delivery to cells, including immune cells, hematopoietic stem cells (HSCs), or liver cells. The conjugates can be formulated in a pharmaceutical composition and can be directly administered to a patient in need thereof, for example, via in vivo administration.

LONG-ACTING PAIN RELIEF FORMULATION

Resumen de: US20260325484A1

0000 The present invention relates to a composition comprising a β-cyclodextrin polymer (a); and at least one compound (b) selected from mycolactone and its derivatives.

RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (TPA) FRAGMENTS AND USES THEREOF

Resumen de: US20260327594A1

0000 The present technology relates to recombinant polypeptides, or nucleotides encoding the same, comprising tissue plasminogen activator (tPA) fragments and uses thereof for treating cardiovascular diseases. In some embodiments, the tPA fragments comprise the kringle 2 domain of tPA.

SARBECOVIRUS NANOVACCINES

Resumen de: US20260325624A1

0000 An immunogenic composition comprising one or more polymers, wherein the polymers comprise one or more monomers of 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), 1,6-bis(p-carboxyphenoxy) hexane (CPH), sebacic anhydride (SA); a SA homopolymer; a CPTEG:CPH copolymer; a CPTEG:SA copolymer; a CPH:SA copolymer; a CPH homopolymer; or a polyester, at least one immunogenic protein of a sarbecovirus; and at least one adjuvant, wherein a first amount of the immunogenic protein and a first amount of the adjuvant are encapsulated within the biodegradable particles, and methods of using the same.

LIPID NANOPARTICLE COMPOSITIONS INCORPORATING AN IMMUNOSUPPRESSANT FOR THE DELIVERY OF SELF-AMPLIFYING RNA

Resumen de: AU2025231951A1

A lipid nanoparticle composition for use in the delivery of a self-amplifying RNA (saRNA) construct in one or more target cells is disclosed. The lipid nanoparticle composition comprises a lipid mixture comprising at least one (ionizable) cationic lipid, at least one helper lipid, a sterol, a corticosteroid such as Dexamethasone, and a least one lipid-polyethylene glycol conjugate. The saRNA construct comprises a first open reading frame which encodes one or more non-structural proteins, and a second open reading frame operatively linked to the first open reading frame. The second open reading frame comprises a coding region which encodes one or more target proteins. In some embodiments, the target proteins comprise one or more therapeutic proteins. In some embodiments, the target proteins comprise one or more one or more Cas proteins and/or variants thereof for use in CRISPR-based gene editing.

CATIONIC LIPIDS AND PREPARATION METHOD THEREOF

Resumen de: US20260325448A1

0000 The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids.

INKT Cell Modulator Liposomal Compositions and Methods of Use

Resumen de: US20260325617A1

0000 Provided herein are compositions including a liposome including Compound A (A), wherein n is 1 (IMM60), 2 (IMM70), or 3 (IMM80), or a salt, ester, solvate, or hydrate thereof, and two or more lipids or salts thereof; and uses thereof, including methods of stimulating an immune response. Also provided herein are liposomes comprising at least one therapeutic agent and a phospholipid bilayer comprising at least two phospholipids selected from 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-phospho-rac-glycerol (DSPG), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and 1,2-dipalmitoyl-sn-glycero-phosphor-rac-(1-glycerol)(DPPG), wherein the phospholipid is substantially devoid of cholesterol, plant sterols, and polyethylene glycolated lipids (PEG lipids).

A PHARMACEUTICAL COMPOSITION COMPRISING 17-AAG AND STAUROSPORINE FOR USE IN THE PREVENTION OR TREATMENT OF CANCER AND DISEASES RESULTING FROM EXCESSIVE CELL PROLIFERATION AND A POLYMER- LIPID NANOPARTICLE CONTAINING THE COMPOSITION

Resumen de: US20260325487A1

0000 A composition comprising 17-AAG and staurosporine for use in the treatment of melanoma, non-small cell lung cancer, pancreatic cancer, mammary gland tumours or gliomas, and a stable polymer-lipid nanoparticle for drug binding and delivery, consisting of a core containing polylactic-co-glycolic acid (PLGA) and polyvinyl alcohol (PVA) and a core envelope containing a mixture of lipids: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DDPC), cholesterol and the ammonium salt 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-amino (polyethylene glycol)-2000 (DSPE-PEG(2000)NH2J.

LIPID PARTICLE

Resumen de: US20260325458A1

An object of the present invention is to provide a lipid particle that can be produced without using a PEG-modified lipid, or that exhibits higher drug effects, safety, or stability than those of a lipid particle produced using a PEG-modified lipid; or that has immunokinetics different from those of a lipid particle produced using a PEG-modified lipid.A lipid particle comprising an ionized lipid, a phospholipid, and a sterol as lipid components of the lipid particle, and a modified polysaccharide containing a hydrophobic group.

STABLE CYCLOSPORINE OPHTHALMIC FORMULATION AND MANUFACTURING PROCESS THEREOF

Resumen de: US20260325603A1

The present invention relates to a stable nanomicellar ophthalmic formulation comprising cyclosporine, hydrogenated 40 polyoxyl castor oil, octoxynol-40, and an aqueous vehicle, wherein the stable nanomicellar ophthalmic formulation is made by a method comprising: a) mixing the hydrogenated 40 polyoxyl castor oil and the octoxynol-40, wherein the mixing produces a Mixture A comprising a water content of less than 3%; b) adding the cyclosporine to the Mixture A to form a Mixture B; and c) mixing the Mixture B with the aqueous vehicle, thereby forming the stable nanomicellar ophthalmic formulation.

IMMUNOLOGICALLY INACTIVE POLY (ETHYLENE GLYCOL) POLYMER DERIVATIVES AND BIOCONJUGATES THEREOF FOR USE AS ALTERNATIVE IN PEGYLATED THERAPEUTICS, PROCESSES FOR THEIR PREPARATION AND THEIR USE

Resumen de: US20260325627A1

0000 Immunological inactive polyether polymers represented by the following formula I: 0000 0000 wherein at least 3% of the residues R include ethylene oxide side chains, oligo(ethylene oxide) side chains and/or glycerol ether side chains and at least 3% of the residues R are hydrogen and R may also be a C1 to C3-alkyloxymethyl side chain. Further, a process for the preparation of the polymers. Finally, the use of the polymers for the preparation of conjugates, especially bioconjugates and the conjugates themselves as alternative for PEGylated therapeutics. The conjugates may include bioactive compounds and/or lipids. They are especially useful for the preparation of vaccines, lipid particles, especially lipid nanoparticles and may be used for the preparation of vaccines against COVID-19.

COMPOSITIONS AND METHODS FOR ACTIVATION AND MATURATION OF IMMUNE CELLS

Resumen de: US20260325565A1

Mammals rely on adaptive immunity to protect against infections and tumors, with the thymus playing a crucial role by producing T cells that target infected or cancerous cells. The thymus, however, undergoes functional decline with age, significantly impairing the immune system in the elderly. To investigate reversing this decline, compositions and methods for activation and differentiation of T cell progenitors in extrathymic tissues are disclosed that stimulate production of differentiated T cells. For example, LNP-mediated delivery of mRNAs encoding DLL-1, IL-7, and FLT3L to the liver is shown to create a temporary site for T cell maturation that enhances T cell-mediated immunity in aged mice without causing autoimmunity. This approach facilitates ectopic T cell development from hematopoietic precursors and activates dendritic cells, providing evidence that engineering adaptive immunity in vivo can effectively mitigate immune aging.

PROCESS FOR PRODUCTION OF POLYOL-FREE VEGETABLE OIL NANOEMULSION USING D-PHASE EMULSIFICATION, POLYOL-FREE VEGETABLE OIL NANOEMULSION, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Resumen de: US20260325446A1

0000 A process for producing a nanoemulsion comprising polyol-free vegetable oil, using the D-phase emulsification (DPE) method and the nanoemulsion comprising polyol-free vegetable oil, pharmaceutical composition and its use as a medicine in the treatment of atopy in mammals.

POLYMER COATED ALKALINE EARTH PHOSPHATE NANOPARTICLE-BASED DELIVERY OF OLIGONUCLEOTIDES

Resumen de: US20260325459A1

0000 The present disclosure provides a biodegradable nanoparticle platform that encapsulates an oligonucleotide, such as a DNAzyme to suppress irf5 expression, which promotes macrophage polarization to an anti-inflammatory state. Herein, the ability to transfect classically activated macrophages, directly suppress IRF5 expression and downstream cytokines, and cause metabolic changes that are indicative of an alternatively activated phenotype is demonstrated. The nanoparticles disclosed herein offer a therapeutic approach to modulate inflammatory pathways in pro-inflammatory macrophages using a biodegradable and non-immunogenic platform.

TARGETED ENCAPSULATION STRATEGIES FOR TREATMENT MODALITIES

Resumen de: US20260325670A1

0000 The invention provides a composition for delivering an active pharmaceutical ingredient (API) and/or active nutraceutical ingredient (ANI) to the basal ganglia of a subject in need thereof comprising a plurality of nanoparticles surface decorated with caffeine, wherein the nanoparticles comprising: at least one API or ANI, at least one emulsifier, at least one emulsifier stabilizer, at least one water miscible solvent, and at least one solid lipid matrix core; and a pharmaceutically or nutraceutically acceptable carrier. The invention further provides methods for delivering active ingredients to the to the basal ganglia of a subject in need thereof and methods for treating Parkinson's disease.

Polydopamine-Coated Nanoparticles in Neurons for Absorption of Ultra-Weak UV Photon Emission to Reduce Downstream Neurotoxic Effects and Neuronal Inflammation in Neurodegenerative Conditions

Resumen de: US20260325453A1

0000 Polydopamine-coated nanoparticles are presented as a novel composition for intracranial delivery, designed to absorb UV photons and mitigate neuroinflammation in brain tissue. These nanoparticles feature a core that includes materials such as silica, gold, iron oxide, or polymeric micelles and are encapsulated within a polydopamine shell. Additionally, biologically active agents can be incorporated to enhance neuroprotection. Methods are provided for treating neurodegenerative diseases (e.g., Parkinson's, Huntington's, ALS, Alzheimer's) or improving glioblastoma therapy by administering the polydopamine-coated nanoparticles directly to affected brain regions via intracerebral injection, intrathecal infusion, or convection-enhanced delivery. Furthermore, the polydopamine-coated nanoparticles hold potential for pharmaceutical applications in developing medicaments targeting neuroinflammation and UV photon absorption within the central nervous system.

PERITONEAL MACROPHAGES COMPRISING A NANOPARTICLE ENCAPSULATING A NUCLEIC ACID MOLECULE AND METHODS OF USE THEREOF

Resumen de: US20260327659A1

The present disclosure provides methods of delivering a nucleic acid molecule to a large peritoneal macrophage (LPM), by contacting a nanoparticle encapsulating the nucleic acid molecule with the LPM, thereby delivering the nucleic acid molecule to the LPM, and compositions generated by these methods. The disclosure also provides methods of delivering an LPM comprising a nanoparticle encapsulating the nucleic acid molecule to an injured tissue in a subject in need thereof, and methods of treating a disease in the subject, e.g., an inflammatory disease, an infectious disease, an autoimmune disease, or a cancer using these LPMs.

ANELLOSOMES AND METHODS OF USE

Resumen de: US20260327654A1

This invention relates generally to anellosomes and compositions and uses thereof.

ANTIFUNGAL LIQUID AND ANTIFUNGAL GEL

Resumen de: US20260325479A1

0000 A composition includes a microemulsion. The microemulsion includes an aqueous phase, an oil phase, and a surface-active agent. The aqueous phase includes water and at least one polyol. The oil phase includes a therapeutically effective amount of tolnaftate and a carrier including Jojoba oil. The microemulsion includes a disperse phase having a particle size of 50 nm or less. A method for making a composition includes forming a first mixture by combining water and at least one polyol; forming a second mixture by combining Jojoba oil, a surface-active agent, and a therapeutically effective amount of tolnaftate; and combining and mixing the first mixture and the second mixture to form a microemulsion. A method of using a composition includes applying the composition to a site of treatment.

WOUND DRESSING

Resumen de: US20260327859A1

A method for controlling fiber cross-alignment in a nanofiber membrane, comprising: providing a multiple segment collector in an electrospinning device including a first and second segment electrically isolated from an intermediate segment positioned between the first and second segment, collectively presenting a cylindrical structure, rotating the cylindrical structure around a longitudinal axis proximate to an electrically charged fiber emitter; electrically grounding or charging edge conductors circumferentially resident on the first and second segment, maintaining intermediate collector electrically neutral; dispensing electrospun fiber toward the collector, the fiber attaching to edge conductors and spanning the separation space between edge conductors; attracting electrospun fiber attached to the edge conductors to the surface of the cylindrical structure, forming a first fiber layer; increasing or decreasing rotation speed of the cylindrical structure to alter the angular cross-alignment relationship between aligned nanofibers in adjacent layers, the rotation speed being altered to achieve a target relational angle.

COMPOSITIONS, METHODS AND USES FOR DETERMINING ATOMIC LAYER DEPOSITION COATING QUALITY AND DISSOLUTION RATES

Resumen de: US20260325460A1

Embodiments of the present disclosure provide novel compositions and methods for determining atomic layer deposition (ALD) coating quality and/or dissolution rates of ALD coated therapeutic agent containing particles. In certain embodiments, in vitro methods can be used to predict or project in vivo dissolution rates of ALD coated therapeutic agent-containing particles, microparticles and/or nanoparticles. In yet other embodiments, formulations disclosed herein can be used to provide improved conditions for determining ALD coating quality or composition, optimum coating layers and/or dissolution rates to release a target therapeutic agent from ALD coating layers. In accordance with these embodiments, improved coating compositions, coating cycles, coating layering and thickness can be determined for improved timed-release delivery of pharmaceutical products to a subject in need thereof.

IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY

Resumen de: US20260327187A1

0000 The present disclosure describes compounds of Formula (1) and pharmaceutically acceptable salts thereof: 0000

FORMULATIONS FOR INTRAOCULAR DELIVERY OF PEPTIDES DERIVED FROM TYPE IV COLLAGEN

Nº publicación: US20260325600A1 22/10/2026

Solicitante:

ASCLEPIX THERAPEUTICS INC [US]
ASCLEPIX THERAPEUTICS, INC.

Resumen de: US20260325600A1

0000 The present disclosure provides pharmaceutical compositions that comprise a microparticle or nanoparticle suspension of a collagen IV-derived peptide or pharmaceutically-acceptable salt thereof, as well as uses of these suspensions for therapy by intraocular delivery. The present disclosure further provides methods for making the microparticle or nanoparticle suspensions.